



SEQIRUS: UNIQUELY FOCUSED ON INFLUENZA

2017 National Adult and Influenza Immunization Summit
11 May 2017

Claudia M. Kelly, MBA, MPH
Senior Director, Value Access and Policy

Disclaimer: all product specifications are subject to change without notice. All trademarks and registered names, brands and logos are the property of their respective owners.

Seqirus 2017 NAIIS GMCC US/Corp/0417/0023

Seqirus has a rich heritage in influenza

- Part of the CSL Group; Seqirus was created in 2015 from the combined strength of bioCSL and Novartis influenza vaccines business
- CSL's influenza experience dates back to the 1918 Spanish Flu Pandemic; vaccine production and pandemic response spans decades
- Novartis pioneered both adjuvanted and cell-based influenza vaccines; built a US cell-culture facility in partnership with BARDA*



* Project funded in part via contracts HSO100200600012C, HHSO100200700030C and HHSO100200900101C.

Seqirus 2017 NAIIS GMCC US/Corp/0417/0023



Seqirus is the world's second largest influenza vaccine manufacturer with innovative technologies and products

- Manufacturing and R&D capabilities across three continents
- Vaccines based on egg and cell-based technologies
- Pandemic partner to Governments around the world
- Early projects on novel formulations and delivery technologies



Holly Springs, US



Liverpool, UK









Melbourne, Australia

Seqirus 2017 NAIS GMCC US/Corp/0417/0023



Seqirus Product Offerings for 2017/2018 Influenza Season

Brand	Current Presentation	Age Indication
	aIIV3 PFS	65+ years
	ccIIV4 MDV, PFS	4+ years
	IIV4 MDV, PFS	18+ years
	IIV3 MDV, PFS	5+ years*
	IIV3 MDV, PFS	4+ years
	Three single-use vials	18+ years

* ACIP recommendation is for use in individuals 9+ years of age


Seqirus 2017 NAIS GMCC US/Corp/0417/0023



Seqirus as a partner in influenza research and education


Continued investment in influenza research

- Unrestricted educational grants for appropriate unsolicited requests
- Investigator initiated studies
- Collaborative research studies
- Market trend analyses



Seqirus 2017 NAIS GMCC US/Corp/0417/0023


Support of independent accredited continuing medical education



<http://resources.us.mdpassport.com/en/kts-flu/>

Partnerships with nurse practitioners, physician assistants, pharmacists and patient organizations about the need for vaccination of appropriate individuals

HCP and patient educational resources



Seqirus
A CSL Company

Market research reinforces the importance of talking to patients and encouraging routine

Top reasons for getting vaccinated (n=1,215)

- Important to avoid the flu
- My doctor recommended it

Top reasons for not getting vaccinated (n=788)

- Not concerned about getting the flu
- Belief that the flu vaccine won't protect against the flu



Trigger for getting the most recent flu vaccine:

- Receiving vaccine at the same time each year

Reference: Seqirus Data on File

Seqirus 2017 NAIS GMCC US/Corp/0417/0023

Seqirus
A CSL Company

Market research reinforces the positive impact immunizers of having flu conversations with patients

Of those vaccinated (n=1,125)

- ~ 50% had a conversation with the immunizer
- Among those who did not have a conversation:
 - > 30% were “extremely” interested and ~ 50% were “moderately” interested in having a conversation
- > 30% of seniors received information about influenza vaccines for 65 years+
- Retailers playing an increasingly important role in flu vaccination



Reference: Seqirus Data on File

Seqirus 2017 NAIIS GMCC US/Corp/0417/0023



FLUAD® (Influenza Vaccine, adjuvanted) Important Safety Information

Indication:

- FLUAD is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is approved for use in persons 65 years of age and older.

Contraindications

- Severe allergic reaction to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.

Warnings and Precautions

- If Guillain-Barré Syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD should be based on careful consideration of the potential benefits and risks.
- The tip caps of the prefilled syringes contain natural rubber latex which may cause allergic reactions in latex sensitive individuals.

Adverse Reactions

- The most common ($\geq 10\%$) local (injection site) adverse reactions observed in clinical studies were injection site pain (25%) and tenderness (21%)
- The most common ($\geq 10\%$) systemic adverse reactions observed in clinical studies were myalgia (15%), headache (13%) and fatigue (13%)

Seqirus 2017 NAIIS GMCC US/Corp/0417/0023



FLUCELVAX® (Influenza Vaccine) Important Safety Information

Contraindication

- Do not administer FLUCELVAX to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine.

Warnings & Precautions

- Guillain-Barré Syndrome (GBS): If GBS has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUCELVAX should be based on careful consideration of the potential benefits and risks.
- Latex: The tip caps of the pre-filled syringes may contain natural rubber latex which may cause allergic reactions in latex-sensitive individuals.
- Preventing and Managing Allergic Reactions: Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
- Syncope: Syncope (fainting) can occur in association with administration of injectable vaccines, including Flucelvax. Syncope can be accompanied by transient neurological signs such as visual disturbance, paresthesia, and tonic-clonic limb movements. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope by maintaining a supine or Trendelenburg position.
- Altered Immunocompetence: After vaccination with FLUCELVAX, immunocompromised individuals, including those receiving immunosuppressive therapy, may have a reduced immune response.
- Limitations of Vaccine Effectiveness: Vaccination with FLUCELVAX may not protect all vaccine recipients against influenza disease.

Seqirus 2017 NAIIS GMCC US/Corp/0417/0023



FLUCELVAX® (Influenza Vaccine) Important Safety Information

Warnings & Precautions

- Altered Immunocompetence: After vaccination with FLUCELVAX, immunocompromised individuals, including those receiving immunosuppressive therapy, may have a reduced immune response.
- Limitations of Vaccine Effectiveness: Vaccination with FLUCELVAX may not protect all vaccine recipients against influenza disease.

Most Common Adverse Reactions

- The most common ($\geq 10\%$) solicited adverse reactions occurring in adults 18-64 years of age within 7 days of vaccination with FLUCELVAX were pain at the injection site, erythema at the injection site, headache, fatigue, myalgia and malaise. The most common ($\geq 10\%$) solicited adverse reactions occurring in adults ≥ 65 years of age within 7 days of vaccination were erythema at the injection site, fatigue, headache and malaise.

Seqirus 2017 NAIIS GMCC US/Corp/0417/0023



AFLURIA® (Influenza Vaccine) Important Safety Information

- Afluria® is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. Administration of Afluria with a needle and syringe is approved for use in persons 5 years of age and older. Administration of Afluria with the PharmaJet® Stratis® Needle-Free Injection System is approved for use in persons 18 through 64 years of age only.
- Afluria is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.
- Administration of CSL's 2010 Southern Hemisphere influenza vaccine was associated with post marketing reports of increased rates of fever and febrile seizures in children predominantly below the age of 5 years as compared to previous years; these increased rates were confirmed by post marketing studies. Febrile events were also observed in children 5 to less than 9 years of age.
- If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give Afluria should be based on careful consideration of the potential benefits and risks.
- If Afluria is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be diminished.

Seqirus 2017 NAIIS GMCC US/Corp/0417/0023



AFLURIA® (Influenza Vaccine) Important Safety Information

- Afluria should be given to a pregnant woman only if clearly needed.
- Afluria has not been evaluated in nursing mothers. It is not known whether Afluria is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Afluria is administered to a nursing woman.
- Antibody responses in persons 65 years of age and older were lower after administration of Afluria as compared to younger adult subjects.
- In children 5 through 17 years of age, most common injection-site adverse reactions observed in clinical studies of Afluria when administered by needle and syringe were pain, redness, and swelling. The most common systemic adverse events were headache, myalgia, irritability, malaise, and fever.
- In adults 18 through 64 years of age, the most common injection-site adverse reactions observed in clinical studies of Afluria when administered by needle and syringe were tenderness, pain, swelling, redness, and itching. The most common systemic adverse reactions observed were muscle aches, headache, and malaise.

Seqirus 2017 NAIIS GMCC US/Corp/0417/0023



AFLURIA® (Influenza Vaccine) Important Safety Information

- In adults 18 through 64 years of age, the most common injection-site adverse reactions observed in clinical studies of Afluria when administered by the PharmaJet Stratis Needle-Free Injection System up to 7 days post-vaccination were tenderness, swelling, pain, redness, itching, and bruising. The most common systemic adverse events within this period were myalgia, malaise, and headache.
- In adults 65 years of age and older, the most common injection-site adverse reactions observed in clinical studies of Afluria when administered by needle and syringe were tenderness and pain.
- Vaccination with Afluria may not protect all individuals.
- Please see full prescribing information for Afluria.
- You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <http://www.fda.gov/medwatch> or call 1-800-FDA-1088.

Seqirus 2017 NAIIS GMCC US/Corp/0417/0023



FLUVIRIN® (Influenza Virus Vaccine) Important Safety Information

- FLUVIRIN should not be administered to anyone with known systemic hypersensitivity reactions to egg proteins (egg or egg products), or to any component of FLUVIRIN, or who has had a life-threatening reaction to previous influenza vaccinations
- If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give FLUVIRIN should be based on careful consideration of the potential benefits and risks
- If FLUVIRIN is administered to immunocompromised persons, including individuals receiving immunosuppressive therapy, the expected immune response may not be obtained. Prior to administration of any dose of FLUVIRIN, the healthcare provider should review the patient's prior immunization history for possible adverse events, to determine the existence of any contraindication to immunization with FLUVIRIN and to allow an assessment of benefits and risks. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine
- The tip caps of the FLUVIRIN prefilled syringes may contain natural rubber latex which may cause allergic reactions in latex sensitive individuals
- Vaccination with FLUVIRIN may not protect all individuals. In clinical trials, the most common adverse events in adults were headache, fatigue, injection site reaction (pain, mass, redness, and induration), and malaise

Seqirus 2017 NAIIS GMCC US/Corp/0417/0023



FLUVIRIN® (Influenza Virus Vaccine) Important Safety Information

- FLUVIRIN should not be administered to anyone with known systemic hypersensitivity reactions to egg proteins (egg or egg products), or to any component of FLUVIRIN, or who has had a life-threatening reaction to previous influenza vaccinations
- If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give FLUVIRIN should be based on careful consideration of the potential benefits and risks
- If FLUVIRIN is administered to immunocompromised persons, including individuals receiving immunosuppressive therapy, the expected immune response may not be obtained. Prior to administration of any dose of FLUVIRIN, the healthcare provider should review the patient's prior immunization history for possible adverse events, to determine the existence of any contraindication to immunization with FLUVIRIN and to allow an assessment of benefits and risks. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine
- The tip caps of the FLUVIRIN prefilled syringes may contain natural rubber latex which may cause allergic reactions in latex sensitive individuals
- Vaccination with FLUVIRIN may not protect all individuals. In clinical trials, the most common adverse events in adults were headache, fatigue, injection site reaction (pain, mass, redness, and induration), and malaise

Seqirus 2017 NAIS GMCC US/Corp/0417/0023



RAPIVAB™ (Peramivir Injection) Important Safety Information

Rapivab™ is indicated for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than 2 days.

- Efficacy of Rapivab was based on clinical trials in which the predominant influenza virus type was influenza A; a limited number of subjects infected with influenza B virus were enrolled.
- Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use Rapivab.
- Efficacy could not be established in patients with serious influenza requiring hospitalization.

Contraindications

None

Seqirus 2017 NAIS GMCC US/Corp/0417/0023



RAPIVAB™ (Peramivir Injection) Important Safety Information

Warnings and Precautions

- Rare cases of serious skin reactions, including Stevens-Johnson syndrome and erythema multiforme have occurred with Rapivab. Appropriate treatment should be instituted if a serious skin reaction occurs or is suspected.
- Patients with influenza may be at an increased risk of hallucinations, delirium and abnormal behavior early in their illness. There have been post-marketing reports (from Japan) of delirium and abnormal behavior leading to injury in patients with influenza who were receiving neuraminidase inhibitors, including Rapivab. Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made, but they appear to be uncommon. These events were reported primarily among pediatric patients. The contribution of RAPIVAB to these events has not been established. Patients with influenza should be closely monitored for signs of abnormal behavior.
- Serious bacterial infections may begin with influenza-like symptoms or may coexist with or occur as complications during the course of influenza. Rapivab has not been shown to prevent such complications.

Seqirus 2017 NAIIS GMCC US/Corp/0417/0023



RAPIVAB™ (Peramivir Injection) Important Safety Information

Adverse Reactions

The most common adverse reaction was diarrhea (8% Rapivab vs 7% placebo).

Lab abnormalities (incidence $\geq 2\%$) occurring more commonly with Rapivab than placebo were elevated ALT 2.5 times the upper limit of normal (3% vs 2%), elevated serum glucose greater than 160 mg/dL (5% vs 3%), elevated CPK at least 6 times the upper limit of normal (4% vs 2%) and neutrophils less than $1.0 \times 10^9/L$ (8% vs 6%).

Concurrent use with Live Attenuated Influenza Vaccine

Antiviral drugs may inhibit viral replication of a live attenuated influenza vaccine (LAIV). The concurrent use of Rapivab with LAIV intranasal has not been evaluated. Because of the potential for interference between these two products, avoid use of LAIV within 2 weeks before or 48 hours after administration of Rapivab unless medically indicated.

Please see full prescribing information for Rapivab.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Seqirus 2017 NAIIS GMCC US/Corp/0417/0023





THANK YOU

CONTACT INFORMATION:

Claudia.Kelly@Seqirus.com

Seqirus 2017 NAIIS GMCC US/Corp/0417/0023